← NEUROCRINE BIOSCIENCES INC NBIX
Market Price
$152.67
Market Cap
$15.16B
P/E Ratio
32.69
Revenue (FY 2025)
↑21.4% YoY
$2.86B
3-Yr CAGR: 24.3%
Net Income
↑40.2% YoY
$478.60M
Net Margin: 16.7%
Free Cash Flow
↑34.4% YoY
$748.70M
FCF Yield: 4.94%
EPS (Diluted)
↑41.9% YoY
$4.67
Basic: $4.81
Return on Equity
Efficiency
14.7%
ROA: 19.0%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (NBIX)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $15.0M | — | $3.8M | $-141.1M | — | $-1.63 | — | $-106.2M | $-110.3M | — |
| FY 2017 | $161.6M | +977.5% | $142.1M | $-142.5M | -1.0% | $-1.62 | +0.6% | $-94.3M | $-101.3M | +8.2% |
| FY 2018 | $451.2M | +179.2% | $420.7M | $21.1M | +114.8% | $0.22 | +113.6% | $101.4M | $76.6M | +175.6% |
| FY 2019 | $788.1M | +74.6% | $72.3M | $37.0M | +75.3% | $0.39 | +77.3% | $152.1M | $137.3M | +79.4% |
| FY 2020 | $1,045.9M | +32.7% | $163.0M | $407.3M | +1,000.5% | $4.16 | +966.7% | $228.5M | $217.6M | +58.5% |
| FY 2021 | $1,133.5M | +8.4% | $102.5M | $89.6M | -78.0% | $0.92 | -77.9% | $256.5M | $233.1M | +7.1% |
| FY 2022 | $1,488.7M | +31.3% | $1,465.5M | $154.5M | +72.4% | $1.56 | +69.6% | $339.4M | $322.9M | +38.5% |
| FY 2023 | $1,887.1M | +26.8% | $1,847.4M | $249.7M | +61.6% | $2.47 | +58.3% | $389.9M | $361.6M | +12.0% |
| FY 2024 | $2,355.3M | +24.8% | $2,321.3M | $341.3M | +36.7% | $3.29 | +33.2% | $595.4M | $557.2M | +54.1% |
| FY 2025 | $2,860.5M | +21.4% | $2,808.4M | $478.6M | +40.2% | $4.67 | +41.9% | $782.7M | $748.7M | +34.4% |
Valuation
Market Price
$152.67
Market Cap
$15.16B
Enterprise Value
N/A
P/E Ratio
32.69
P/B Ratio
4.72
FCF Yield
4.94%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
98.18%
Operating Margin
21.64%
Net Margin
16.73%
Return on Equity (ROE)
14.71%
Return on Assets (ROA)
18.97%
Asset Turnover
1.13x
Revenue 3-Yr CAGR
24.32%
Financial Health & Liquidity
Current Ratio
3.39
Cash Ratio
0.96
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$713.00M
Total Debt
N/A
Book Value / Share
$32.35
Cash Flow Efficiency
Operating Cash Flow
$782.70M
Capital Expenditures (CapEx)
$34.00M
Free Cash Flow
$748.70M
OCF / Revenue
27.36%
FCF / Revenue
26.17%
FCF 3-Yr CAGR
32.36%
Per Share Metrics
EPS (Diluted)
$4.67
EPS (Basic)
$4.81
Dividends / Share
N/A
Book Value / Share
$32.35
EPS YoY Growth
41.95%
Balance Sheet (FY 2025)
Total Assets
$2.52B
Total Liabilities
$743.40M
Stockholders' Equity
$3.25B
Current Assets
$2.52B
Current Liabilities
$743.40M